Isam Albaba, MBSS, from the department of thoracic medicine & surgery at Temple University Hospital.

CT Air Trapping Metric May Predict Post-BLVR Pneumothorax Risk

Functional air trapping measured specifically within emphysematous regions of the lung, rather than across the whole lobe, may offer a meaningful pre-procedural signal for pneumothorax risk following bronchoscopic lung volume reduction (BLVR) in patients with 

chronic obstructive pulmonary disease (COPD)

, according to research presented at the 

American Thoracic Society (ATS) 2026 International Conference

The retrospective analysis, presented by Isam Albaba, MBBS, from Temple University, examined quantitative CT (QCT) parameters in 59 patients who underwent BLVR, 27 of whom developed post-procedure pneumothorax and 32 of whom did not. Using Coreline software to analyze paired inspiratory and expiratory CT scans, investigators evaluated a range of metrics, including lobar volumes, fissure completeness, change in mean lung density, and functional air trapping (fAT), defined as the proportion of lung voxels demonstrating air retention between the 2 scans.

Among all evaluated parameters, functional air trapping specifically within emphysematous lung regions (fAT-E) emerged as the strongest predictor of post-BLVR pneumothorax. In the full cohort, fAT-E reached statistical significance 

 =.017), with ROC curve analysis identifying an optimal threshold of approximately 25% (AUC 0.68; 67% sensitivity, 75% specificity). Total fAT across the whole lobe did not reach significance.

, Albaba noted that the analysis evolved after the abstract was submitted.

 Restricting the fAT-E analysis to higher-quality scans, defined as those with at least a one-liter volume change between inspiration and expiration, strengthened the signal considerably (

 =.002; AUC 0.79), with specificity rising to 94% at a threshold of approximately 26.5%.

"When we applied the functional air trapping just in the emphysema areas, not in the whole lung, not in the whole lobe, we found a very statistically significant prediction of pneumothorax," Albaba said.

Many BLVR candidates have 2 viable target lobes, with decisions currently informed by tools such as VQ scanning to assess relative perfusion. A validated fAT-based metric could add another dimension to that calculus—one oriented specifically around pneumothorax risk.

"If I target this lobe, is the chance of pneumothorax happening 50% as opposed to the other one, where there's 10%? That will probably take me more towards the latter target because there's less likelihood of pneumothorax happening, but I will still be able to get the same benefits of the volume reduction and the improvement in quality of life," Albaba said.

Beyond target selection, Albaba outlined a longer-term research question: whether very high fAT in emphysematous areas might predict persistent air leak, which is a more serious and less common outcome than pneumothorax itself. While most post-BLVR pneumothoraces resolve with chest tube drainage and patients are discharged without recurrence, a subset requires prolonged drainage, ultimately necessitating valve removal and forfeiture of procedure benefit. Identifying those patients before the procedure could inform patient selection decisions.

"Trying to identify patients using that metric…could be a future direction," Albaba said. "If somebody has very high functional air trapping in emphysematous areas, that may actually put them out of the [running for] this procedure, and maybe just look at other things that we can do for our COPD patients."

On the question of real-world accessibility, Albaba acknowledged that quantitative CT analysis software, including Coreline, remains unavailable at many institutions, though adoption is growing. He framed prospective validation as the prerequisite for broader clinical uptake.

"We will be able to prospectively validate, but we have to do that first before we can say that we can now just basically make it a standard of care or make it an available tool for physicians to use to predict pneumothorax before the procedure even happens," Albaba said.

Editor’s note: Albaba has no reported disclosures.

) Quantitative CT Predictors of Pneumothorax After Bronchoscopic Lung Volume Reduction: The Role of Air Trapping and Lobar Volume Interactions. Poster presented at: American Thoracic Society (ATS) International Conference 2026 on May 19 in Orlando, Florida

Albaba I, Deller E, Lalwani A, Dachert S, Criner G. Functional air trapping predicts pneumothorax after BLVR. Poster presented at American Thoracic Society International Conference 2026; May 16 –21; Orlando, FL. Poster P354.

Videos

Functional air trapping in emphysematous lung regions may predict pneumothorax after BLVR, per ATS 2026 data presented by Isam Albaba, MBBS, from Temple University.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Amit Gupta, MBBS, DNB, is a diabetologist, executive director of the Global Metabolic Health Alliance, and chair of the International Diabetes Federation (IDF) Education Committee.

Diabetes Dialogue: The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this special episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in Ner Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Amit Gupta, MBBS, DNB, diabetologist, executive director of the Global Metabolic Health Alliance, and chair of the International Diabetes Federation (IDF) Education Committee, to discuss the state of diabetes care and treatment in India compared to the US.

To begin the episode, Gupta introduces the mission of the IDF, highlighting its role as a worldwide federation of scientific societies and patient organizations focused on improving diabetes education, policy, advocacy, and access to care. The conversation explores how diabetes management differs across regions, emphasizing that while the underlying disease mechanisms and available therapies may be similar, access to medications, technologies, healthcare infrastructure, and education varies significantly between countries.

Gupta discusses the impact of semaglutide becoming available as a generic therapy in India following patent expiration, describing how reduced costs have improved access to a medication previously limited by affordability barriers. The group considers how increased availability of GLP-1 receptor agonists may transform diabetes and obesity management, while also emphasizing that pharmacologic therapies alone cannot address the global metabolic health crisis. Gupta notes the importance of maintaining focus on long-term lifestyle changes, including nutrition, physical activity, and sustainable weight management, as essential components of comprehensive care.

The discussion then shifts to diabetes education and the need for more individualized, patient-centered approaches. Gupta highlights that education must be adapted to regional and cultural contexts, explaining that the challenges faced by a person with diabetes in the United States, Africa, India, or other parts of the world may differ substantially, even though diabetes distress and the burden of daily decision-making are shared experiences. He emphasizes that access to technology, such as continuous glucose monitoring, does not eliminate the need for education and support.

Isaacs, Bellini, and Gupta also address the growing challenge of misinformation online and the role of healthcare professionals in helping patients navigate unreliable sources of health information. Gupta explains that clinicians must approach misinformation constructively by providing evidence-based guidance rather than simply dismissing patients’ beliefs, reinforcing the importance of translating scientific evidence into practical recommendations that patients can incorporate into their daily lives.

The group further examines disparities in the availability of diabetes educators worldwide. Gupta notes that while some regions have established professional pathways for diabetes care and education specialists, many areas lack standardized training, recognition, or policy support to sustain these roles. He stresses that building effective diabetes education systems requires collaboration with policymakers to demonstrate the long-term benefits of structured education programs.

The episode concludes with Gupta discussing his work developing a global consensus framework on lifestyle as the foundation of metabolic health. The conversation reinforces that advances in medications and technology must be paired with equitable access, effective education, and sustainable lifestyle interventions to reduce the global burden of diabetes and improve outcomes for people living with metabolic conditions.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Gupta reports disclosures with Lilly, Abbott Diabetes, and the International Diabetes Federation.

Gupta A. IDF Perspective on Diabetes Self-Management Education and Support (DSMES): PWD Perspective. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Gupta A. Uptake of Continuous Glucose Monitoring in Under-Resourced Populations. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Podcasts

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Peter Lio, MD
Credit: Northwestern University

 has approved a maintenance regimen of lebrikizumab (Ebglyss) 250 mg administered once every 8 weeks for adults and children aged 12 years and older weighing at least 40 kg with 

, Eli Lilly and Company announced on June 9, 2026.

Lebrikizumab, an interleukin-13 (IL-13) inhibitor, received initial US approval in 2024 as a first-line biologic with once-monthly maintenance dosing and, more recently, long-term data have shown durable disease control with the agent through up to 4 years of continuous treatment.

 The every-8-week option reduces injection frequency for patients maintaining adequate clinical response.

"The option to extend EBGLYSS maintenance dosing to every eight weeks represents an important moment for patients living with moderate-to-severe atopic dermatitis," said Peter Lio, MD, primary investigator of the ADjoin study and clinical assistant professor of dermatology and pediatrics, Northwestern University. "This new dosing regimen without mandatory topicals gives patients a new option to manage their condition based on individual needs. It's about meeting patients where they are in their lives."

Lebrikizumab every-8-week dosing data from the ADjoin extension

The approval rests on longitudinal exposure-response modeling and clinical data from a 32-week extension of the phase 3 ADjoin long-term trial (NCT04392154). The extension evaluated open-label lebrikizumab 250 mg administered once every 8 weeks or once every 4 weeks in adult patients and adolescents aged 12 to 17 years weighing at least 40 kg with moderate to severe disease across select countries.

Eligible participants had completed the 100-week ADjoin long-term study, with enrollment drawn from the phase 3 ADvocate 1 and ADvocate 2 monotherapy trials, the ADore adolescent open-label study, and the ADopt-VA vaccine response study. Patients received the every-8-week or every-4-week dose regardless of their previous ADjoin regimen or response status at extension baseline.

Under the updated label, maintenance dosing of 250 mg every 4 weeks or every 8 weeks begins after an induction period of 250 mg every 2 weeks through week 16, or later once adequate clinical response is achieved.

Lebrikizumab safety profile through 32 weeks of extended dosing

No new safety signals emerged in lebrikizumab safety data from the 32-week every-8-week ADjoin extension, according to Lilly. No patients discontinued treatment due to adverse events through 32 weeks.The most common adverse reactions reported with lebrikizumab, occurring in at least 1% of patients, are conjunctivitis, injection site reactions, and herpes zoster.

According to the company, lebrikizumab is now the only approved option in this indication offering as few as 6 maintenance injections per year, with no required topical therapy from treatment initiation.

"Living with moderate-to-severe atopic dermatitis often means dealing with a cycle of symptoms and time-intensive treatment routines during and in-between flares," said Kristin Belleson, president and CEO of the National Eczema Association. "This new option can ease the burden, allowing patients to spend less time thinking about managing their condition on a daily basis."

Lilly reported coverage with all 3 major national pharmacy benefit managers, with 94% of commercially insured patients covered through national health plans. The company is pursuing expanded Medicaid and Medicare coverage and offers co-pay assistance for eligible, commercially insured patients through Lilly Support Services.

Eli Lilly and Company. FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. Press release. Published June 9, 2026. Accessed June 10, 2026. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglyssr-lebrikizumab-lbkz-one-maintenance

Silverberg J, et al. Lebrikizumab every 8 weeks as maintenance dose provides long-lasting response in patients with moderate-to-severe atopic dermatitis. Presented at: Fall Clinical Dermatology Conference; 2025.

HCPLive. Lebrikizumab for Atopic Dermatitis Leads to 4 Years of Clearance, Itch Reduction. 

https://www.hcplive.com/view/lebrikizumab-atopic-dermatitis-leads-4-years-clearance-itch-reduction

. Published April 2, 2026. Accessed June 10, 2026.

Articles

FDA authorized lebrikizumab 250 mg every 8 weeks as maintenance for moderate-to-severe atopic dermatitis in patients ≥12 years, ≥40 kg, enabling reduced injection frequency after induction. Approval leveraged exposure–response modeling plus 32-week open-label ADjoin extension data in participants completing 100 weeks of long-term therapy. Label permits transition to q4w or q8w maintenance after q2w dosing through week 16 or once adequate response occurs. Safety through 32 weeks showed no new signals, with conjunctivitis, injection-site reactions, and herpes zoster most common.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

FDA News

FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis

Natasha Mesinkovska, MD, PhD, is a dermatologist and researcher at the University of California, Irvine School of Medicine Department of Dermatology.

What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata

 reviews AbbVie’s supplemental new drug application for upadacitinib (Rinvoq) in 

, Natasha Mesinkovska, MD, PhD, highlighted the potential impact that an additional approved therapy could have on younger patients, long-term disease management, and broader recognition of alopecia areata as a chronic autoimmune condition.

team, Mesinkovska emphasized the unique burden alopecia areata can place on adolescents and their families. She noted that while some young patients may appear outwardly resilient, the psychosocial impact of hair loss during adolescence is often substantial. Based on her experience treating patients and participating in clinical trials, she suggested that successful treatment can have meaningful effects beyond hair regrowth alone, improving confidence and quality of life during a particularly vulnerable stage of development.

The inclusion of adolescents aged 12 years and older in the UP-AA phase 3 program was therefore a notable aspect of the submission, particularly given the limited number of approved treatment options currently available for younger patients with severe disease.

Mesinkovska also addressed the significance of complete scalp hair regrowth, one of the secondary endpoints achieved in the clinical program. She noted that expectations for treatment success in alopecia areata have evolved considerably in recent years. Historically, clinical trial responders were defined as patients achieving at least 80% scalp hair coverage, a benchmark that was itself considered highly meaningful. However, newer therapies are now raising expectations by demonstrating the possibility of near-complete or complete regrowth in some patients.

According to Mesinkovska, these outcomes help establish a higher standard for future therapies and reflect growing ambitions among both clinicians and patients seeking optimal disease control.

Despite recent advances, she noted that several important unmet needs remain. The underlying cause of alopecia areata is still not fully understood, limiting the ability to predict who will develop the disease or how it might be prevented. Additionally, disease flares can still occur even among patients receiving treatment, highlighting the need for therapies that provide durable long-term control.

Mesinkovska also pointed to the ongoing need for treatment strategies patients and clinicians can feel comfortable using over extended periods. While safety data for JAK inhibitors in alopecia areata have thus far been reassuring, she noted that the field continues to seek approaches that minimize treatment burden while maintaining efficacy.

Looking ahead, Mesinkovska noted a potential approval of upadacitinib could further reinforce understanding of alopecia areata as a chronic autoimmune disease rather than a purely cosmetic condition. Given the drug’s established use across multiple inflammatory diseases, she highlighted its potential expansion into alopecia areata may help underscore the immunologic nature of the disorder and its broader impact on patient health.

Disclosures: Mesinkovska has served on advisory boards for Arena Pharmaceuticals, Concert Pharmaceuticals, La Roche-Posay Laboratorie Pharmaceutique, Lilly ICOS LLC, Nutrafol, and Pfizer Inc.; as a speaker for Eli Lilly; and as an investigator for AbbVie, Arcutis, Inc., Arena Pharmaceuticals, Kyowa Hakko Kirin Pharma, Inc., Lilly ICOS LLC, Merz Aesthetics, and Pfizer Inc. She received honoraria for advisory board and speaking activities, research funding from Merz Aesthetics and Pfizer Inc., and no compensation for investigator roles with AbbVie, Arcutis, Arena Pharmaceuticals, Kyowa Hakko Kirin Pharma, and Lilly ICOS LLC.

AbbVie. AbbVie submits application to FDA for upadacitinib (Rinvoq) for adults and adolescents with severe alopecia areata. Published April 28, 2026. Accessed June 9, 2026. 

https://www.prnewswire.com/news-releases/abbvie-submits-application-to-fda-for-upadacitinib-rinvoq-for-adults-and-adolescents-with-severe-alopecia-areata-302754816.html

Smith T. Upadacitinib sNDA Submitted to FDA for Severe Alopecia Areata. HCPLive. April 28, 2026. Accessed June 9, 2026. 

https://www.hcplive.com/view/upadacitinib-snda-submitted-to-fda-for-severe-alopecia-areata

Natasha Mesinkovska, MD, PhD, speaks on the potential impact that an additional approved therapy like upadacitinib could have on younger patients with alopecia areata.

Alopecia

How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD

 submission for upadacitinib (Rinvoq) in severe alopecia areata represents another important step forward for a patient community that had few effective treatment options until just a few years ago, according to Natasha Mesinkovska, MD, PhD, a dermatologist and affiliated expert with the National Alopecia Areata Foundation.

, Mesinkovska emphasized the rapid evolution of the alopecia areata treatment landscape since the first FDA approval of a JAK inhibitor for the condition in 2022. She described the progress as the culmination of decades of work by researchers, clinicians, and patient advocates.

“Hair is having its moment,” Mesinkovska said, noting that individuals with alopecia areata historically had limited therapeutic options and often faced the choice of concealing their hair loss or embracing it publicly without effective treatment available.

She highlighted the importance of expanding the number of approved therapies within the JAK inhibitor class, particularly because alopecia areata commonly affects younger individuals. If approved, upadacitinib would provide another treatment option for both adolescents and adults aged 12 years and older, a population with significant unmet needs.

Discussing the phase 3 UP-AA data that supported the submission, Mesinkovska stressed that additional therapies are valuable because patients do not respond uniformly to treatment. She compared the expanding therapeutic armamentarium to having multiple keys available for different locks.

Mesinkovska also noted the study findings reinforce a pattern already observed with JAK inhibitors, namely that higher doses may produce more robust efficacy but can also be associated with a greater likelihood of adverse events. As a result, clinicians must continue balancing efficacy and safety considerations when selecting therapies.

Reflecting on the treatment landscape since the approval of baricitinib, Mesinkovska acknowledged that adoption of newer therapies has been somewhat slower than many specialists initially anticipated. She attributed this to caution among both physicians and patients. Clinicians have sought additional real-world experience with the medications, while some patients with longstanding disease remain hesitant after experiencing previous treatment disappointments.

Nevertheless, she believes confidence in these therapies continues to grow as more patients receive treatment and gain experience with newer options.

Mesinkovska also pointed to what she perceives as an increase in alopecia areata cases following the COVID-19 pandemic, whether due to greater recognition of the disease or potential autoimmune triggers. As awareness and demand for treatment increase, she said additional approved therapies could further strengthen the field and provide patients with greater confidence that meaningful treatment options are available.

This interview on a possible upcoming therapeutic option for severe alopecia areata highlights information regarding upadacitinib (Rinvoq) and its potential.

Payel Gupta, MD, allergist and immunologist at Ease Allergy Clinic and Mount Sinai.

Payel Gupta, MD, discusses how IgE, FeNO, and type 2 comorbidities inform biologic choice and when a lack of response warrants switching agents.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Biologic Selection in Severe Asthma: Biomarkers, Comorbidities, When to Switch

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

Clofutriben Phase 2a Data Show Cardiometabolic Benefits in Type 2 Diabetes

The FDA marked bemotrizinol as first new active ingredient on the over-the-counter (OTC) sunscreen monograph since the 1990s.

FDA Adds Bemotrizinol as First New Sunscreen Ingredient in Decades

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Learn what the first-ever CKM syndrome guideline means for screening, treatment, and the connection between heart disease, kidney disease, diabetes, and obesity.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

AHA, ACC Issue First-Ever Clinical Guideline for Cardiovascular-Kidney-Metabolic Syndrome

John Buse, M.D., Ph.D., demystifies the baseline role of cortisol as an essential life hormone and introduces the striking clinical reality that autonomous cortisol hypersecretion silently drives treatment resistance in one-quarter of patients with difficult-to-control type 2 diabetes.

Video Series

Understanding the Basics

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data

Gerard Criner, MD, is chair and professor of thoracic medicine and surgery at Lewis Katz School of Medicine at Temple University and director of the Temple Lung Center.

Phase 2 findings presented at ATS 2026 by Gerald Criner, MD, show pegtarazimod cut supplemental oxygen needs in hospitalized AE-COPD patients for up to 60 days.

Pegtarazimod Reduces Supplemental Oxygen Need in Hospitalized AE-COPD Patients 

This segment of the May episode of The Medical Sisterhood highlights key points regarding the impacts of role models on young patients in dermatology.

The Influence of Physician Role Models on Young Patients, With Lisa Swanson, MD

Aboul-Fettouh describes the protracted path many patients travel before receiving a correct AA diagnosis-often 6 to 12 months or longer-and explains the psychosocial weight that accumulates during that delay.

The Patient Journey to Diagnosis: Delays, Barriers, and the Psychosocial Toll

Aboul-Fettouh clarifies the broad meaning of "alopecia" as a category, distinguishes alopecia areat as an autoimmune subtype, and addresses common patient misconceptions-including misplaced self-blame-that complicate early education and care.

Latest News

CT Air Trapping Metric May Predict Post-BLVR Pneumothorax Risk

Diabetes Dialogue: The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB

FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis

What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata

How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD